Full history for every metric is available with a Kvantra account
Seagen Inc. (SGEN)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 482 | 655 | 917 | 2,176 | 1,574 | 1,962 | 2,300 |
| Operating profit | $m | -613 | -791 | |||||
| Net profit | $m | -126 | -223 | -63 | 614 | -674 | -610 | -750 |
| EPS reported | $ | -3.30 | -4.01 | |||||
| Operating cashflow per share | $ | -2.46 | -2.46 | |||||
| Capex per share | $ | 0.42 | 0.42 | |||||
| FCF per share | $ | -2.88 | -2.88 | |||||
| Free cash flow | $m | -531 | -701 | |||||
| Net debt | $m | -1,692 | -1,237 | |||||
| Book value equity | $m | 2,804 | 2,550 | |||||
| Book value per share | $ | 15.18 | 13.56 | |||||
| Number of shares | m | 184.68 | 188.14 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 8.46 | 16.92 | |||||
| P/S LTM | x | 12.09 | 18.76 | |||||
| P/FCF LTM | x | -44.69 | -61.54 | |||||
| EV/EBITDA LTM | x | -37.61 | -53.36 | |||||
| EV/Sales LTM | x | 11.95 | 18.22 | |||||
| Earnings Yield LTM | % | -2.57% | -1.44% | |||||
| FCF Yield | % | -2.24% | -1.62% | |||||
| Quality | ||||||||
| ROE | % | -21.77% | -20.80% | |||||
| ROIC | % | -21.46% | -21.46% | |||||
| Operating margin | % | -31.24% | -31.24% | |||||
| Gross margin | % | 79.10% | 79.10% | |||||
| FCF/Sales | % | -27.06% | -27.06% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +24.65% | +23.40% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -12.22 | -6.18 | |||||
| Net Debt/EBITDA | x | 0.44 | 0.44 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -7.13% | -2.87% | |||||
| Net debt/Equity | x | -0.60 | -0.49 | |||||
| Gross debt/equity | x | 0.02 | 0.04 | |||||
Company overview
Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Seagen Inc. (SGEN)
Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free